Nordimaprit
Nordimaprit is a reversible, non-competitive H3 receptor antagonist with a pKi value of 5.94. Nordimaprit exhibits essentially no activity against H1 receptors and only weak agonistic activity against H2 receptors. Nordimaprit induces selective chemotaxis of eosinophils in rabbit eyes, triggering severe eosinophilic uveitis and ocular symptoms such as corneal edema, opacity, and inflammation. Nordimaprit reduces melanin content and inhibits tyrosinase activity, and exerts toxic effects on melanoma cells. Nordimaprit can be used in studies related to anterior uveitis and melanoma.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 17124-82-2
- Formel: C5H13N3S
- Molecular Weight:147.24
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
In Vitro
Nordimaprit binds to H3 binding sites in rat brain cortex homogenates with a pKi of 5.94, showing no differentiation between H3A and H3B binding site subtypes[2].
Nordimaprit (0.5-10 μM; 110 min) acts as a reversible noncompetitive H3 receptor antagonist in mouse brain cortex slices, reducing both the maximum inhibitory effect and potency of histamine with an apparent pD'2 of 5.55[2].
Nordimaprit (2 μM; 30 min) binds reversibly to presynaptic H3 receptors in mouse brain cortex slices, as pre-exposure to the compound does not persistently reduce histamine's inhibitory activity[2].
Nordimaprit (50 μM; 4 days) reduces melanin content to 72.31% and tyrosinase activity to 61% of control levels in human melanoma MM418 cells[3].
Nordimaprit (0.03-1 mM; 48-66 h) inhibits Con A-induced activation of human peripheral blood mononuclear lymphocytes with an IC50 of 0.03 mM, with cell mortality increasing in a dose-dependent manner alongside activation inhibition[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Dutch Belted (pigmented); albino[1]
-
Dosage:0.21 M
-
Administration:topical; three times daily; 12+ consecutive days; continued for an additional 48 hours if uveitis developed
-
Result:Induced eosinophil uveitis in 5 of 5 treated eyes with onset at 5-10 days when administered alone.
Induced eosinophil uveitis in 5 of 5 treated eyes with onset at 2-3 days when administered with proparacaine.
Induced eosinophil uveitis in 5 of 5 treated eyes with onset at 2-3 days when administered with proparacaine and cimetidine.
Produced severe corneal opacification, a marked fibrinoid response in the aqueous humor, either transient miosis followed by marked mydriasis or direct marked mydriasis, and loss of intact iris stromal melanocytes.
Maintained peripheral blood eosinophil counts at 2-3% before, during, and after treatment.
Chemical Information
-
CAS. Nr. 17124-82-2
-
Molecular Weight 147.24
-
Formel C5H13N3S
-
SMILES
N=C(SCCN(C)C)N
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)